Drug intelligence / Profile preview

Herbal ingredient (B)

Development stage: Preclinical
Lead developer: Korea Pharma
Administration: Oral, Topical

Overview

Herbal ingredient (B) is a botanical-based therapeutic candidate currently in preclinical development by Korea Pharma for the treatment of eczema. Part of the company's research into traditional Korean medicine (Hanbang) components, this asset is being evaluated for its potential to alleviate symptoms of inflammatory skin disease. Specific details regarding its phytochemical composition or molecular targets have not been publicly disclosed by the sponsor.

Other names: 한방성분(B)

Targets

NF-κBATF4 (Activating transcription factor 4)TAK1 (Transforming growth factor beta–activated kinase 1)RK (Ribokinase)SFK (SRC family kinases)SYK (Spleen Tyrosine Kinase)JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on Herbal ingredient (B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herbal ingredient (B).

Explore the full profile